Infinitus Systems vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI voice automation platform handling healthcare phone calls — benefits verification, prior auth, and referrals — at scale. San Francisco CA; raised $52M+ (a16z, GV);
About
Infinitus Systems is a healthcare AI company that automates the high-volume, repetitive phone call work that burdens provider administrative teams. Founded in 2019 and headquartered in San Francisco, California, Infinitus has raised more than $52 million from investors including Andreessen Horowitz and GV. The company's AI voice agent, called Maya, conducts real-time phone conversations with insurance payers to verify benefits, check prior authorization status, confirm referrals, and gather other eligibility information on behalf of healthcare providers.\n\nTraditionally, benefits verification and prior authorization follow-up requires large teams of staff members spending hours on hold and navigating complex phone trees. Infinitus replaces this manual process with an AI agent that operates around the clock, completing calls faster than human agents and capturing structured data directly into provider workflows. Customers include health systems, specialty practices, revenue cycle management outsourcers, and digital health companies that need to scale patient access operations without proportionally growing headcount.\n\nThe platform is designed for interoperability, delivering results through APIs and direct integrations with EHR systems, practice management software, and RCM platforms. Infinitus has processed tens of millions of healthcare transactions and continues to expand the scope of calls its AI can handle, with a roadmap that includes scheduling, referral coordination, and patient-facing outreach.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.